vimarsana.com

Latest Breaking News On - Shanghai changhai hospital - Page 1 : vimarsana.com

Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting

/PRNewswire/ On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumors, announced that the clinical.

United statesMinmin sunTianhang luoFirst affiliated hospital of zhejiang universitySuzhou immunofoco biotechnology co ltdAmerican society of clinical oncologyImmunofoco biotechClinical oncologyShanghai changhai hospitalFirst affiliated hospitalZhejiang universityRecommended dose

Immunofoco Biotech To Unveil Solid Tumor CAR-T Programs Clinical Trial Data At 2024 ASCO Meeting

CHICAGO, June 1, 2024 /PRNewswire/ On June 1st, 2024, Immunofoco Biotech, a company dedicated to developing cell therapy products for solid tumor

United statesMinmin sunTianhang luoAmerican society of clinical oncologyFirst affiliated hospital of zhejiang universitySuzhou immunofoco biotechnology co ltdImmunofoco biotechClinical oncologyShanghai changhai hospitalFirst affiliated hospitalZhejiang universityRecommended dosePeri cruiser

China approves AI-based movement disorder analysis software

It extracts quantitative data for clinical decision-making from analysing videos of patient's movements.

United statesUnited kingdomCity ofZhou dongChina national medical products administrationKings college londonModas movement dysfunction assessment softwareMovement dysfunction assessment softwareShanghai changhai hospitalRune labs

Record short videos to assess Parkinson s disease, NERVTEX s First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved

/PRNewswire/ NERVTEX s MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)-.

Zhou dongDong boyaChina national medical products administrationHealthcare of the national university systemModas movement dysfunction assessment softwareAsian innovation research allianceCentre for innovationMovement dysfunction assessment softwareFirst in class artificialMachine learningMedical deviceShanghai changhai hospitalNational university healthcare systemInnovative medical technology productsTherapeutics innovationFind award

Intensive BP Lowering Harmful in Acute Ischemic Stroke

The ENCHANTED2/MT trial, which was investigating intensive lowering of blood pressure in acute ischemic stroke patients after mechanical thrombectomy, has been stopped early due to safety concerns.

New south walesUnited kingdomNoord hollandYvo roosCraig andersonJeyaraj pandianNational healthUnited kingdom medical research councilResearch futures fund of australiaUniversity medical centerWorld stroke organizationTechnology commission of shanghai municipalityResearch council of australiaChristian medical collegeUniversity of new south walesResearch council

vimarsana © 2020. All Rights Reserved.